Researchers are rapidly focused on retatrutide, a promising drug from Eli Lilly, as a potential breakthrough in physique reduction . Distinct from many previous approaches, retatrutide is a double -action compound targeting both GLP-1 and GIP, substances that affect satiety and glucose control .